SEARCH

SEARCH BY CITATION

References

  • 1
    Bhattacharyya T, Iorio R, Healy WL. Rate of and risk factors for acute inpatient mortality after orthopaedic surgery. J Bone Joint Surg Am 2002; 84-A: 56272.
  • 2
    Blom AW, Taylor AH, Pattison G, Whitehouse S, Bannister GC. Infection after total hip arthroplasty: the Avon experience. J Bone Joint Surg Br 2003; 85: 9569.
  • 3
    Poss R, Thornhill TS, Ewald FC, Thomas WH, Batte NJ, Sledge CB. Factors influencing the incidence and outcome of infection following total joint arthroplasty. Clin Orthop Relat Res 1984; 182: 11726.
  • 4
    Wilson MG, Kelley K, Thornhill TS. Infection as a complication of total knee-replacement arthroplasty: risk factors and treatment in sixty-seven cases. J Bone Joint Surg Am 1990; 72: 87883.
  • 5
    Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 90716.
  • 6
    Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Dougados M, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003) [published erratum appears in Ann Rheum Dis 2004;63:114]. Ann Rheum Dis 2003; 62 Suppl 2: ii29.
  • 7
    Giles JT, Bathon JM. Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 2004; 19: 32034.
  • 8
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 9
    Coventry MB. Treatment of infections occurring in total hip surgery. Orthop Clin North Am 1975; 6: 9911003.
  • 10
    Gillespie WJ. Prevention and management of infection after total joint replacement. Clin Infect Dis 1997; 25: 13107.
  • 11
    Zimmerli W, Ochsner PE. Management of infection associated with prosthetic joints. Infection 2003; 31: 99108.
  • 12
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098104.
  • 13
    Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 46: 256570.
  • 14
    Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 2004; 25: 3315.
  • 15
    Hultgren O, Eugster HP, Sedgwick JD, Korner H, Tarkowski A. TNF/lymphotoxin-alpha double-mutant mice resist septic arthritis but display increased mortality in response to Staphylococcus aureus. J Immunol 1998; 161: 593742.
  • 16
    Phillips K, Husni ME, Karlson EW, Coblyn JS. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 2002; 47: 1721.